The researchers, led by Jasleen Saini from the University of Toronto’s Division of Neurosurgery, note that AI algorithms now delineate tumor margins, classify molecular signatures, and forecast outcomes before a single incision is made. In neurosurgery, AI supports preoperative planning, image registration, augmented-reality overlays, intraoperative navigation, and real-time scene interpretation. But these applications introduce risks not captured by image-only benchmarks, including registration error, brain shift during surgery, latency, device interoperability issues, and the consequences of erroneous guidance delivered in real time.

Models that perform strongly in controlled studies may show reduced performance across new institutions, scanners, workflows, or patient populations. Scanner calibration, institutional heterogeneity, and underrepresentation of vulnerable populations continue to limit generalizability. The team argues that existing reporting guidance, medical-device standards, regulatory requirements, and machine learning operations each address important parts of the problem but were not designed to serve as a unified, stage-gated clinical-evidence pathway across the full AI lifecycle.

The proposed IDEAL-AI framework organizes evidence generation across five stages—Idea, Development, Exploration, Assessment, and Long-term study—and three concurrent domains: validation; governance, regulation, and ethics; and patient and system outcomes. At the Idea stage, AI development should begin with a defined clinical need and intended use rather than a technical challenge in search of an application. Technical, fairness, safety, human-factors, and clinical endpoints should be specified before model tuning begins.

A critical distinction the framework draws is between retrospective model development and prospective live exploration. Development covers model refinement using retrospective data, requiring separated training, tuning, and locked test sets along with version control. Exploration begins prospective live clinical use across increasing site and clinician diversity, focusing on generalizability, workflow integration, and safety under real conditions. This separation prevents broad clinical claims from being inferred from retrospective development alone.

The Assessment phase requires adequately powered, multi-institutional comparative evaluation of a locked system with a prospectively specified protocol. Randomization is preferred when feasible. The Long-term phase ensures oversight continues beyond authorization, using real-world dashboards to track calibration, subgroup performance, drift, and safety signals over time. Predefined alert, stop, rollback, and recalibration rules should be linked to change-control processes such as the FDA’s Predetermined Change Control Plans.

The team illustrates the framework with a worked example: glioma segmentation for surgical planning. Despite strong Dice similarity coefficients reported in systematic reviews, the field often stops at early stages due to frequent reuse of curated public datasets and limited prospective evaluation. Under IDEAL-AI, a segmentation tool would need to demonstrate not just technical overlap but how the contour changes planning, what errors matter near eloquent brain structures, and which downstream outcomes are plausibly affected.

The framework also confronts automation bias—the tendency for clinicians to over-rely on AI advice, particularly dangerous in high-stakes settings like neurosurgical navigation where false precision can lead to irreversible harm. The researchers argue that mitigation requires human-factors design, prospective evaluation, clinician training, usable uncertainty displays, and clear escalation pathways. Systems should actively support rather than merely permit clinician challenge.

IDEAL-AI is designed as an orchestration layer rather than a competitor to existing frameworks. It complements facility-level governance programs, registry infrastructure for post-deployment monitoring, reporting guidelines, and operational pipelines for reproducible deployment. The researchers emphasize that a technically compliant system may still lack evidence of workflow fit or patient benefit, while a clinically promising pilot may remain unready for scale because of inadequate documentation or subgroup evaluation.

The measure of success, the team concludes, will not be how quickly AI is implemented but how rigorously it is evaluated and governed. Clinicians, regulators, and developers share a collective duty to ensure that accuracy, equity, and accountability evolve in tandem. The next era of AI in medicine will be defined not by who adopts it first, but by how effectively it improves patient outcomes.

The IDEAL framework that underpins this proposal has a notable history in surgery. First articulated more than a decade ago by collaborative groups of surgical researchers, it was designed to bring order to the evaluation of new procedures and devices, where early enthusiasm and small single-center series often outpaced rigorous evidence. Its adaptation to AI reflects a recognition that machine-learning tools share key features with surgical innovations: they evolve iteratively, their real-world behavior can differ from controlled testing, and their harms may only become visible after widespread adoption. The authors argue that this lineage gives IDEAL-AI a practical advantage over frameworks built solely around software, because it was conceived for technologies whose safety depends on both the artifact itself and the skill of the person deploying it.

The distinction between the Exploration and Assessment stages deserves particular attention. In many current deployment pathways, a tool that performs acceptably at one institution is rapidly scaled across a health system without a formal comparative evaluation. IDEAL-AI instead requires that live exploration with increasing numbers of sites and clinicians precede any adequately powered multi-institutional comparison, and that the comparison itself use a locked version of the system with a prospectively specified protocol. This sequencing mirrors how new surgical techniques traditionally earn acceptance, and it creates natural decision points where expansion can be paused if safety signals or performance degradation emerge.

The framework’s emphasis on prespecified endpoints addresses a well-documented weakness in the AI literature. Retrospective studies frequently report favorable results because the metrics, thresholds, and subgroups analyzed were chosen after the results were seen. By requiring that technical, fairness, human-factors, and clinical endpoints be fixed before model tuning begins, IDEAL-AI reduces the flexibility that enables such selective reporting. The inclusion of fairness metrics as a required domain rather than an optional consideration reflects growing evidence that performance can vary substantially across patient subgroups defined by age, sex, ethnicity, comorbidity, or imaging characteristics, with underrepresented populations bearing the greatest risk of silent failure.

The glioma segmentation example illustrates why downstream consequences matter more than headline metrics. A segmentation model might achieve an impressive overlap score on a public benchmark while producing contour errors that are clinically trivial in some brain regions and catastrophic near eloquent cortex. The framework’s insistence on asking how a contour changes surgical planning, which errors matter, and which outcomes are plausibly affected shifts evaluation from abstract similarity measures toward the decisions that actually shape patient care. This logic applies equally to radiology, where a detection tool’s false-negative rate in a specific subgroup may matter far more than its average sensitivity.

Post-market surveillance receives particular emphasis because AI systems can degrade silently. Unlike a static surgical implant, a deployed model is exposed to evolving scanner fleets, changing acquisition protocols, shifting referral patterns, and updates to upstream software. Drift may occur gradually and without any alarm, which is why the authors call for real-world dashboards tracking calibration, subgroup performance, and safety signals, with predefined alert, stop, rollback, and recalibration rules. Linking these operational triggers to regulatory mechanisms such as Predetermined Change Control Plans provides a pathway for manufacturers to update models while preserving oversight, rather than forcing a choice between frozen tools and uncontrolled change.

The proposal also engages with the practical reality that most healthcare AI governance today is fragmented. Adoption decisions are often shaped by local procurement, and critical judgments about validation, safety, and oversight fall to individual organizations with widely varying resources and expertise. The authors suggest that multidisciplinary Clinical AI Oversight Boards, including clinicians, data scientists, ethicists, quality leaders, patient representatives, and regulatory experts, can anchor accountability at the institutional level, while linked health-data systems and federated evaluation extend performance tracking across institutions without centralizing patient-level data. This layered approach acknowledges that no single actor—regulator, vendor, hospital, or clinician—can carry the full burden of accountability alone.

Ultimately, the framework’s most consequential claim may be its redefinition of success. By judging AI not on adoption speed or benchmark accuracy but on reproducible clinical benefit, IDEAL-AI reframes the incentive structure for developers, purchasers, and clinicians alike. A tool that cannot demonstrate benefit across diverse sites, patient populations, and workflow conditions would fail to progress, regardless of how impressive its test-set performance appears. Whether the field embraces such discipline, or continues to reward rapid deployment, will shape the safety and trustworthiness of clinical AI for years to come.

Subject of Research: From scanner to scalpel: adapting IDEAL for accountable AI in radiology and image-guided neurosurgery

Article Title: From scanner to scalpel: adapting IDEAL for accountable AI in radiology and image-guided neurosurgery

Article References: Saini, J., Jassar, S., Adams, S. J., Alli, S. B., Colak, E., & Wilson, J. R. (2026). From scanner to scalpel: adapting IDEAL for accountable AI in radiology and image-guided neurosurgery. Frontiers in Radiology, 6, Article 1979076. https://doi.org/10.3389/fradi.2026.1979076

Image Credits: AI Generated

DOI: 10.3389/fradi.2026.1979076

Keywords: scanner, scalpel, adapting, IDEAL, accountable, radiology, image-guided, neurosurgery, scientific research

The central idea behind the study is neuromodulation, the deliberate adjustment of nerve activity to change the function of an organ. For the heart, the relevant nerves belong to the autonomic nervous system, the network that operates largely outside conscious control. Sympathetic branches act like an accelerator, speeding the heart when the body demands more oxygen, while parasympathetic branches act as a brake, slowing it during rest and recovery. Clinicians have long known that adjusting this balance can treat rhythm disorders, but the tools available to do so have been crude, invasive, or both. Focused ultrasound offers a way to deliver energy to a precisely defined volume of tissue deep inside the body, stimulating or suppressing neural structures without any incision.

Ultrasound neuromodulation has attracted growing interest over the past decade because sound waves interact with tissue in ways that electrodes cannot. An ultrasound transducer can focus acoustic energy at a target millimeters across, several centimeters beneath the skin, while leaving intervening tissue essentially untouched. The mechanical and thermal effects of the focused beam can alter the excitability of nerve fibers, changing how likely they are to fire action potentials. Depending on the acoustic parameters chosen, the same technology can excite or inhibit neural activity, giving researchers a reversible dial for nervous system function rather than a simple on-off switch.

What distinguishes the new work is the emphasis on image guidance. Delivering energy to the region around the heart is technically demanding because the target moves constantly with each heartbeat and shifts with every breath. The researchers integrated their ultrasound system with imaging that allowed them to track and compensate for this motion, keeping the acoustic focus locked on the intended neural target as the body moved. This kind of closed-loop control is widely regarded as essential if ultrasound neuromodulation is ever to leave the laboratory, because even small targeting errors could disperse the acoustic energy to unintended structures or miss the nerve tissue altogether.

The reported outcome is that this image-guided stimulation could regulate heart rate. By directing focused ultrasound at cardiac neural targets, the team demonstrated that the technique could influence the pace of the heartbeat in a controlled fashion, adjusting the balance between the nerves that accelerate the heart and those that slow it. Regulation, rather than simple stimulation, is the crucial claim. A clinically useful therapy would need to raise or lower heart rate on demand, or damp pathological overactivity, and the study presents its approach as capable of that kind of bidirectional control.

The technical machinery required for this achievement is considerable. High-intensity focused ultrasound systems of the kind used for ablating tumors deliver enough energy to destroy tissue, but neuromodulation typically operates at far lower intensities, below thresholds that would cause lasting damage. The acoustic parameters, including frequency, pulse duration, and repetition rate, determine whether the beam primarily excites nerve fibers, suppresses them, or produces transient heating that changes their behavior. Finding parameter sets that reliably modulate cardiac nerves without harming the surrounding myocardium is one of the field’s central challenges, and the published work contributes data toward that goal.

Why does this matter for medicine? Disturbances of heart rate and rhythm are among the most common and lethal problems in clinical cardiology. Abnormally fast rhythms, abnormally slow rhythms, and chaotic fibrillation all arise from malfunctions in the heart’s electrical control system, and the autonomic nerves that supply the heart are deeply implicated in many of these conditions. Catheter ablation, in which a physician threads wires into the heart and burns small areas of tissue, is effective for some disorders but is invasive and carries procedural risk. Drugs can modulate autonomic tone but act throughout the body, producing side effects far from the heart. A noninvasive, focal, and reversible method for adjusting cardiac nerve activity would fill a genuine gap in the therapeutic arsenal.

The study also speaks to a broader trend in bioelectronic medicine, a field built on the idea that many diseases can be treated by adjusting the electrical signals carried by nerves rather than by delivering chemicals. Researchers have implanted electrodes on the vagus nerve to treat epilepsy and inflammatory conditions, and others have explored stimulation of the carotid sinus and spinal cord for cardiovascular indications. Ultrasound offers these same possibilities from outside the body, which would eliminate implantation surgery and infection risk. The heart, with its well-mapped autonomic innervation and its easily monitored output, is a natural proving ground for the concept, because heart rate itself provides an immediate, continuous readout of whether the neuromodulation is working.

As with any early-stage study, important questions remain before patients could benefit. The durability of the effect, the precise neural structures targeted, the safety margins for repeated sessions, and the translation of results across species are all matters that will require further investigation. The team’s own account presents the work as a demonstration of feasibility: that image guidance can keep a focused ultrasound beam on a moving cardiac target, and that the resulting neuromodulation is sufficient to regulate heart rate. Scaling from demonstration to therapy will demand larger and longer studies, refinement of the targeting algorithms, and careful assessment of any off-target effects on neighboring tissue.

Nevertheless, the publication marks a noteworthy step for a technology that many researchers hope will reshape how medicine interacts with the nervous system. The combination of focused ultrasound with real-time imaging transforms neuromodulation from a procedure requiring precision hardware implanted inside the body into something closer to an examination: the patient lies still, the imaging system tracks the target, and the acoustic beam delivers its influence without a single incision. If subsequent studies confirm and extend these results, the day may come when clinicians tune the heart’s rhythm the way this study did, with sound alone, guided by images, and reversed the moment the therapy ends.

The physics underlying this approach rewards a closer look, because it explains both the promise and the difficulty of the method. Ultrasound waves at the megahertz frequencies typically used for neuromodulation travel through soft tissue at roughly fifteen hundred meters per second and can be steered by phasing the emissions of hundreds of individual elements on a transducer array. Each element fires with a slightly different delay, so that the wavefronts arrive simultaneously at a chosen point, constructive interference concentrates the acoustic pressure there, and tissue elsewhere receives comparatively little energy. This electronic steering means the focus can be repositioned in milliseconds purely by changing the timing signals, a property that pairs naturally with the fast feedback demanded by a beating heart.

The choice of neural target is equally consequential. The heart’s autonomic control is organized around ganglionated plexi, clusters of neurons embedded in the epicardial fat pads near the pulmonary veins, the superior vena cava, and the atria. These microganglia act as local integration centers, relaying and processing signals from the vagus nerve and the sympathetic chain before they reach the cardiac conduction system. Cardiac surgeons and electrophysiologists have known for decades that disturbing these clusters alters atrial rhythm tendencies, which is precisely why they represent attractive targets for noninvasive modulation. Delivering acoustic energy to such small structures, however, requires submillimeter accuracy sustained over many cardiac cycles.

Motion compensation of this kind borrows heavily from techniques developed in radiation oncology, where tumor-tracking linear accelerators adjust beam delivery to a patient’s respiratory cycle. The cardiac problem is harder still, because the heart moves faster than the lungs and exhibits beat-to-beat variability. A successful tracking system must therefore anticipate where the target will be when each acoustic pulse arrives, rather than simply following its past position, and any latency in the imaging chain must be accounted for in the control algorithm.

Safety considerations extend beyond the avoidance of thermal injury. Regulatory frameworks for medical ultrasound, built around indices that estimate heating and the potential for cavitation, will need to be interpreted carefully for a therapy whose intended effect is functional rather than destructive. Repeated exposure of the same neural tissue raises questions about cumulative changes in nerve excitability, and the possibility that acoustic energy scattered by ribs or lung tissue could stimulate unintended structures deserves systematic study. The chest wall itself presents an acoustic obstacle, since bone reflects and absorbs ultrasound strongly, so coupling of the beam through an intercostal window is a practical constraint on positioning.

The experimental logic of using heart rate as an endpoint also deserves emphasis. Unlike modulation of deeper brain circuits, where effects must be inferred indirectly, cardiac neuromodulation produces a continuous, quantitative, beat-by-beat readout that can be captured with noninvasive electrocardiography. This tight feedback loop makes the heart an ideal model system for validating the principles of image-guided acoustic neuromodulation generally, and lessons learned here may well inform applications to the peripheral and central nervous system, where comparable targeting and monitoring challenges await solutions.

Subject of Research: Noninvasive image-guided focused ultrasound neuromodulation of cardiac autonomic nerves to regulate heart rate

Article Title: Image-guided cardiac focused ultrasound neuromodulation regulates heart rate

Article References: Piao, X., Wei, Y., Yao, X., Xu, Z., Pan, J.-J., Hu, P., & Cheng, B. (2026). Image-guided cardiac focused ultrasound neuromodulation regulates heart rate. Communications Engineering. https://doi.org/10.1038/s44172-026-00774-6

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00774-6

Keywords: focused ultrasound, neuromodulation, heart rate, autonomic nervous system, image guidance, cardiology, bioelectronic medicine, ultrasound therapy, cardiac nerves, noninvasive stimulation, Image-guided, cardiac